InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
2
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-27.7%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Smith Jason Drew. Officer active across 1 company, notably UroGen Pharma Ltd.. Aggregated, 13 reports have been recorded. Breakdown: 2 buys · 1 sell. Total volume traded: €71k. Activity tracked since 17 May 2021. The latest transaction was disclosed on 1 February 2024 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations13 total
2,500 sharesOrdinary SharesSEC:0001437749-25-002685:0
3,333 sharesOrdinary SharesSEC:0001437749-24-029038:0
417 shares@ US$15.788.6% of flowOrdinary SharesSEC:0001437749-24-003155:0
834 sharesOrdinary SharesSEC:0001437749-24-003018:0
8,334 sharesOrdinary SharesSEC:0001437749-23-025204:0
833 sharesOrdinary SharesSEC:0001437749-23-002338:0
8,333 sharesOrdinary SharesSEC:0001437749-22-021776:0
833 sharesOrdinary SharesSEC:0001209191-22-006387:0
833 sharesOrdinary SharesSEC:0001209191-22-006387
8,333 sharesOrdinary SharesSEC:0001209191-21-067440:0
8,333 sharesOrdinary SharesSEC:0001209191-21-067440
2,500 shares@ US$15.710.0023% mcap50.0% of flowCommon StockSEC:0001209191-21-033399:0
Ideal exit: 11 Feb 2022 (T+270)
2,500 shares@ US$15.7150.0% of flowCommon StockSEC:0001209191-21-033399
Ideal exit: 11 Feb 2022 (T+270)
13 of 13 declarations
About Smith Jason Drew
Jason Drew Smith is a director at UroGen Pharma Ltd.
